An observational study in Heart Failure, sponsored by Satelia. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Satelia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.
Among the 448 studies in Heart Failure with a site in France, this one is the 3rd largest by enrollment of the 161 observational ones that give a count, is one of 28 that started in 2018, is one of 161 observational ones, and was the 448th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18–90
University Hospital, Montpellier · Sites in France
Ages 18+
Oslo University Hospital · Sites in France, United States, Belgium and 7 more countries
Ages 18+
AstraZeneca · Sites in France, United States, Argentina and 29 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
448 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 28 · Phase 3 70 · Phase 4 15
First in 1983; this study’s year is marked. 28 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32,380 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 196 across the 282 interventional studies, 321 across the 161 observational. Of the 290 that completed or were terminated, 74 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 448 have an industry lead sponsor. The 10 most frequent:
Satelia is the lead sponsor of 5 studies on the registry; none are open to participants now.
Satelia has 5 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
28 of the studies in Heart Failure with a site in France that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020263Phase 3Pr Bruno LEVYEffect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock | 2027-02-03 |
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06518694Phase 3Assistance Publique - Hôpitaux de ParisBeta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction | 2027-10 |
Add all 28 to your calendar (.ics) → With an account.
Among the 448 studies in Heart Failure with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective, multicenter observational cohort study evaluates adults with heart failure enrolled in the Satelia® Cardio telemonitoring program in France between 28 August 2018 and 6 July 2026. Participants are classified according to the location of their follow-up center into a French overseas departments cohort, comprising Martinique, Guadeloupe, and La Réunion, and a mainland France cohort. The study evaluates regional differences in clinical characteristics, telemonitoring organization and engagement, guideline-directed medical therapy (GDMT) use, and follow-up status.
This study is a retrospective, multicenter comparative cohort analysis based on routinely collected data from the Satelia® Cardio heart failure telemonitoring program. All adult patients with heart failure enrolled in the program between 28 August 2018 and 6 July 2026 were eligible for inclusion. Participants are categorized according to the geographic location of the center responsible for their follow-up. The overseas cohort comprises patients followed in ten centers across Martinique, Guadeloupe, and La Réunion, while the comparison cohort comprises patients followed in mainland France. Patients whose follow-up center could not be determined were excluded, leaving 32,380 patients for analysis.
Variables assessed include age, sex, NYHA functional class, LVEF, heart failure etiology, cardiovascular risk factors and comorbidities, monitoring mode and frequency, questionnaire adherence, triggered alerts, duration of follow-up, guideline-directed medical therapy, follow-up status, and reasons for discontinuation. Guideline-directed medical therapy is evaluated according to therapeutic class, including beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors. Patients are considered exposed to a therapeutic class if at least one prescription for that class was recorded at any time during follow-up. Three-class and four-class GDMT are also assessed; four-class GDMT denotes recorded exposure to all four foundational treatment classes and does not require documented simultaneous use at a single time point. Analyses of NYHA class, LVEF, and heart failure etiology are restricted to participants with available data. Guideline-directed medical therapy is additionally assessed according to left ventricular ejection fraction category.
Adults with heart failure enrolled in the Satelia® Cardio telemonitoring program in France between 28 August 2018 and 6 July 2026. Participants were classified according to the location of the center responsible for their follow-up as either the French overseas departments cohort, comprising Martinique, Guadeloupe, and La Réunion, or the mainland France cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Follow-up center could not be determined from the extracted data.
Adults with heart failure enrolled in the Satelia Cardio remote monitoring program and followed by one of nine participating centers located in Martinique, Guadeloupe, or La Réunion.
Adults with heart failure enrolled in the Satelia Cardio remote monitoring program and followed by participating centers located in mainland France.
Clinical Profile of Participants by Geographic Cohort
Demographic and clinical characteristics of participants in the French overseas departments and mainland France cohorts, including age, sex, New York Heart Association functional class, left ventricular ejection fraction category, heart failure etiology, cardiovascular risk factors, and comorbidities.
Time frame: At enrollment in the Satelia Cardio remote monitoring program
Telemonitoring Organization and Engagement by Geographic Cohort
Telemonitoring organization and engagement, including monitoring mode, monitoring frequency, questionnaire adherence, triggered clinical alerts, and duration of follow-up, compared between the French overseas departments and mainland France cohorts.
Time frame: From enrollment through the end of follow-up, up to 6 July 2026.
Guideline-Directed Medical Therapy Exposure by Geographic Cohort
Proportion of participants with recorded exposure to beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors. Exposure to a therapeutic class is defined as at least one prescription for that class recorded at any time during follow-up. Three-class and four-class GDMT are also assessed, with four-class GDMT defined as recorded exposure to beta-blocker, renin-angiotensin system inhibition (ARNI, ACEi, or ARB), MRA, and SGLT2i; concurrent use at a single time point is not required.
Time frame: During telemonitoring follow-up, through 6 July 2026
Retention Under Telemonitoring and Reasons for Discontinuation
Proportion of participants remaining under telemonitoring at the end of follow-up and distribution of recorded reasons for discontinuation, including death, patient-initiated discontinuation, and care-team-initiated discontinuation.
Time frame: Status at the end of follow-up, through 6 July 2026.
Guideline-Directed Medical Therapy by Left Ventricular Ejection Fraction Category
Guideline-directed medical therapy exposure assessed within reduced left ventricular ejection fraction (\<40%), mildly reduced left ventricular ejection fraction (40-49%), and preserved left ventricular ejection fraction (≥50%) categories. GDMT exposure is based on recorded prescriptions during follow-up.
Time frame: During telemonitoring follow-up, through 6 July 2026.
Plan to share: No — Individual participant-level data will not be made publicly available because the study is based on pseudonymised routine-care health data subject to applicable data-protection and governance requirements.
Ran from Aug 2018 to primary completion in Jul 2026, 94 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.